CION Ameerpet
"How much of my tumour can be removed?" is one of the most important questions in brain surgery. This guide explains the answer in plain language — and why the goal is always maximal safe resection.
When a surgeon operates on a brain tumour, they cannot always remove every last cell. The extent of resection is simply how much of the tumour they were able to take out. It is measured by comparing the MRI taken before surgery with a scan done within a day or two afterwards.
This one measurement matters a great deal. For many tumours, published evidence gathered by NCCN and the European Association of Neuro-Oncology (EANO) links a more complete removal with better tumour control and, for several tumour types, longer survival. That is why so much planning goes into it — and why the goal of brain tumour surgery is always maximal safe resection: taking out as much tumour as possible without harming the parts of the brain you rely on every day.
But "more" is never removed at any cost. Some tumour sits in or around areas that control speech, movement, vision or memory. Removing tumour there could cause lasting harm. The surgeon's job is to find the balance — the most complete removal that still keeps you safe and functional. That decision is reviewed at a multidisciplinary tumour board.
For glioblastoma and many gliomas, a larger extent of resection is one of the few factors surgeons can influence that is repeatedly linked to better outcomes. NCCN and EANO glioma guidelines both recommend maximal safe resection as the surgical goal — removing as much tumour as possible while protecting neurological function — because both the amount removed and the amount left behind (residual tumour) affect how the tumour behaves afterwards.
You may hear several terms used to describe how much tumour was removed. Here is what each one means:
A subtotal resection or biopsy is not a failed operation. Often it is the safest, most sensible plan — protecting your function while giving the diagnosis needed to treat the rest with radiation or systemic therapy. Book a free consultation to understand which applies to your tumour.
It is a fair and common question. There are two main reasons a surgeon may not remove every trace of a tumour:
This is exactly why the surgical goal is described as maximal safe resection — the word "safe" is not optional. The right amount of tumour to remove is a careful judgement based on your scans, the tumour type and its grade, decided together with you.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get an honest explanation of how much of your tumour can be safely removed, and the plan that follows — from a coordinated neuro-oncology team. Decisions for healing, not billing.
Across many tumour types, how much tumour is removed is one of the strongest factors linked to how well treatment works. Here is why it carries so much weight — and where the evidence is strongest:
Extent of resection is not the only thing that matters. Tumour type, grade and molecular markers, your age and general health all play a part. But it is one of the few factors that surgery can directly influence — which is why it is planned so carefully.
The value of surgery is not only about how much tumour is removed — it is also about the tissue it provides. The sample taken during your operation is sent for molecular testing (markers such as IDH mutation and MGMT methylation). NCCN and EANO guidelines use these results — together with the tumour grade and the residual tumour on the post-operative MRI — to decide whether radiation and systemic therapy are needed and which approach works best.
Modern techniques let surgeons push the extent of resection higher while protecting the brain areas you depend on. These tools are supported by NCCN and EANO guidance. At CION, all of these neurosurgical procedures are coordinated with accredited neurosurgical partners, while the imaging, planning, molecular testing and follow-on care are delivered by CION.
Neuronavigation builds a three-dimensional map from your MRI that acts like a GPS for the operation. As the surgeon works, the system shows exactly where the instruments are in relation to the tumour and to critical structures nearby. This lets the team reach the tumour through the safest route and know how close they are to areas that must be protected. It is one of the core tools that allows a more complete removal without straying into healthy, functioning brain — improving both safety and the extent of resection.
When a tumour sits in or near the areas controlling speech, language or movement, an awake craniotomy can remove more tumour while protecting these functions. Because the brain itself feels no pain, the patient can be gently woken during the removal and asked to talk, name objects or move a hand. The surgeon watches these responses in real time and knows exactly where to stop. This mapping lets the team safely increase the extent of resection in areas that would otherwise be considered too risky to approach. EANO and NCCN both support awake mapping for tumours in these "eloquent" locations.
Sometimes an updated scan is taken during the operation — with intra-operative MRI or ultrasound — to check how much tumour remains before closing up. Because the brain can shift slightly once surgery begins, these live images help confirm whether more tumour can still be safely removed. When residual tumour is found in a safe location, the surgeon can continue and improve the extent of resection in the same operation, rather than the patient needing a second procedure.
Some high-grade tumours can be made to glow under a special light after the patient takes a fluorescent marker before surgery. This fluorescence guidance helps the surgeon distinguish tumour tissue from healthy brain that can look almost identical to the naked eye. By highlighting the edge of the tumour, it can help achieve a more complete removal. Whether this technique is suitable depends on the tumour type and is decided by the coordinated neurosurgical team.
An MRI is usually done within 24 to 48 hours of surgery to measure the extent of resection while swelling is still minimal. This scan shows whether a gross total, near-total or subtotal resection was achieved and how much residual tumour remains. That measurement, combined with the molecular testing on the sample and the tumour grade, is what the tumour board uses to plan the radiation and systemic therapy that may follow. It is a key step, not an afterthought.
Important: which of these tools are used depends on your tumour's exact location and type. Your brain tumour treatment team will recommend the safest approach to achieve the best extent of resection for you.
If some tumour cannot be safely removed, it is not ignored — it becomes the focus of the treatment that follows surgery. The plan depends on the tumour grade and the molecular results:
CION delivers the radiation therapy, systemic therapy, steroid and seizure management, and supportive care that follow surgery directly — all coordinated through a tumour board that reviews every case. This is why a subtotal resection can still lead to a very good plan: the extent of resection sets the starting point, and the treatment that follows takes it from there.
The amount of tumour to remove is a major decision, and a second opinion is especially worthwhile in these situations:
CION offers a free written second opinion reviewed by a neuro-oncology tumour board. We walk this journey with you — with transparent costs and decisions made for healing, not billing. You can also explore the full brain cancer and tumour hub or read about what brain tumour surgery involves. Request your free review or call 18002028726.
A free written review of your imaging and plan — especially valuable if awake mapping or molecular testing has not yet been discussed, or if a tumour has been called inoperable.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Extent of resection is simply how much of the tumour the surgeon is able to remove. It is measured by comparing the MRI before surgery with a scan done soon after. A gross total resection (GTR) means all of the tumour visible on MRI was removed. A subtotal resection means part of the tumour remained — usually because it wrapped around vital structures. A biopsy only takes a small sample for diagnosis without removing the tumour. The extent achieved is one of the strongest factors linked to outcomes for many tumours, which is why it is discussed carefully before surgery.
For many tumours, yes — but not at any cost. Large studies summarised by NCCN and EANO show that a greater extent of resection is linked to longer survival and better tumour control in high-grade gliomas such as glioblastoma, and in many lower-grade gliomas. However, the benefit only holds when removal is safe. Taking out tumour that is tangled in speech, movement or vision areas can cause lasting harm that outweighs any survival gain. That is why the goal is maximal safe resection — removing as much as possible while protecting healthy function.
A gross total resection (GTR) means the surgeon removed all of the tumour that could be seen on the MRI — there is no visible residual tumour on the scan taken after surgery. A subtotal resection (STR) means some tumour was deliberately left behind, usually because it was too close to critical brain areas or major blood vessels to remove safely. A subtotal resection is not a failed operation — it is often a planned, sensible decision that protects speech, movement or vision. Any residual tumour can then be treated with radiation therapy or systemic therapy.
Brain tumours — especially gliomas — often do not have a clean edge. Their cells spread into surrounding healthy brain like roots, so a "complete" removal on MRI does not mean every tumour cell is gone. More importantly, some tumour sits in or wraps around eloquent areas that control speech, movement, vision or memory, or around major blood vessels. Removing tumour there could cause permanent disability. The surgeon weighs the benefit of removing more against the risk of harm, aiming for the most complete removal that still keeps you safe and functional.
Modern tools let surgeons push the extent of resection higher while protecting function. Neuronavigation acts like a real-time GPS built from your MRI. Awake craniotomy with brain mapping lets the patient talk or move while the tumour near speech and movement areas is removed, so the surgeon knows exactly where to stop. Intra-operative imaging and fluorescence guidance help show tumour that is hard to see with the eye. These techniques are supported by EANO and NCCN guidelines. At CION, all neurosurgery is coordinated with accredited neurosurgical partners, while imaging, molecular testing and follow-on care are delivered by CION.
Residual tumour is not ignored — it is treated. After surgery, the tissue removed is sent for molecular testing (such as IDH and MGMT), and a follow-up MRI measures how much tumour remains. For high-grade tumours, radiation therapy (IMRT/IGRT) and systemic therapy usually follow to control what could not be removed surgically. Focused radiation can target residual tumour precisely. Every case is reviewed at a multidisciplinary tumour board so the plan after surgery matches the tumour type, grade and how much was removed.
It often matters a great deal. For many lower-grade gliomas, published evidence links a more complete removal with longer time before the tumour grows back and, in some studies, longer survival. Because these tumours can grow slowly over years, achieving a good extent of resection early — safely — can delay the need for radiation or chemotherapy. Benign, well-defined tumours such as many meningiomas can sometimes be fully removed with an excellent outlook. The right goal always depends on the tumour type, its location and the balance of benefit against risk, decided with your team.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.